Trestle Biotherapeutics
YC W21San Diego, US · Founded 2020 · 2 employees · 3 known investors
Find your way into Trestle Biotherapeutics
919 people in our graph share verified history with the Trestle Biotherapeutics team — schools, employers, funds. One of them is your warm intro.
Matt Wittunlockedknows Ben Shepherd · together at University of Washington (overlapped)
×10knows the team · via Y Combinator
knows the team · via Yale University School of Medicine
Trestle Biotherapeutics develops bioengineered implantable tissues designed to treat end-stage renal disease, aiming to get patients off dialysis and eventually provide replacement organs. The company uses stem cell biology, biofabrication, and 3D bioprinting technologies to create functional kidney tissue for patients with kidney failure.
Founders & leadership· Y Combinator alumni (W21)
Trestle Biotherapeutics was founded in 2020 by Ben Shepherd, Alice Chen, and Alice Chen, PhD.
BS
Ben ShepherdinCo-founder & CEOBen Shepherd is a vascular biologist and tissue engineer who previously held an academic position at Yale School of Medicine before spending over a decade in industry developing research teams focused on 3D bioprinting and biofabrication technologies for tissue engineering applications.
AC
Alice CheninCo-Founder & CSOAlice Chen has 20+ years of research experience in developmental biology, stem cell biology, and tissue engineering. She founded Trestle Biotherapeutics to develop therapeutic tissue for chronic kidney disease treatment.
AC
Alice Chen, PhDinCo-founder and Chief Scientific OfficerChen spent four years at Organovo Holdings, where she rose from Associate Director of R&D for tissue applications to Director of Research and Preclinical Development, and previously led cell reprogramming at ESI BIO, a division of BioTime, and R&D work in cellular differentiation and reprogramming services at Stemgent. She completed a postdoctoral fellowship at the Harvard Stem Cell Institute.
BS
Ben Shepherd, PhDCo-Founder and Chief Executive Officer
Investors · 3
Competitors · 3
by search overlap
Fortis Life Sciences8 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Krystalbio8 shared keywordsKrystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.
Solu7 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Trestle Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Trestle Biotherapeutics do?
- Trestle Biotherapeutics develops bioengineered implantable tissues designed to treat end-stage renal disease, aiming to get patients off dialysis and eventually provide replacement organs. The company uses stem cell biology, biofabrication, and 3D bioprinting technologies to create functional kidney tissue for patients with kidney failure.
- Who founded Trestle Biotherapeutics?
- Trestle Biotherapeutics was founded by Ben Shepherd, Alice Chen, Alice Chen, PhD in 2020.
- Who are Trestle Biotherapeutics's investors?
- Trestle Biotherapeutics's investors include Y Combinator, Draper Associates, Axial VC.
- Where is Trestle Biotherapeutics headquartered?
- Trestle Biotherapeutics is headquartered in San Diego, US.